7 results on '"Ahmadpour S"'
Search Results
2. Effect of Iron Deficiency Anemia on Blood Glucose and Insulin Resistance in Women with Type II Diabetes: A Single-group, Clinical Interventional Study.
- Author
-
Parham M, Tavasoli GR, Arsang-Jang S, Habibi MA, Dameshgi DO, Pashaei MR, Ahmadpour S, and Vafaeimanesh J
- Subjects
- Humans, Female, Middle Aged, Adult, Iran, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 blood, Insulin Resistance, Anemia, Iron-Deficiency etiology, Anemia, Iron-Deficiency drug therapy, Blood Glucose analysis, Blood Glucose metabolism, Ferrous Compounds therapeutic use, Ferrous Compounds administration & dosage
- Abstract
Aims: Iron deficiency anemia (IDA) is one of the disorders recently associated with an increase in insulin resistance (IR) and, consequently, diabetes mellitus (DM) affection by causing oxidative stress. In this study, we look at how IDA may contribute to developing type II diabetes mellitus (T2DM), controlling diabetes, and reducing IR in women with T2DM., Methods: In this single group, clinical interventional study, we enrolled 40 women with T2DM and IDA. Before and after intervention with ferrous sulfate tablets, their blood glucose (BG) levels and IR levels were evaluated. This study was approved by the Ethics Committee of Qom University of Medical Sciences (ethics code: IR.MUQ.REC.1397.031) and registered at the Iranian Center for Clinical Trials (No. IRCT20170215032587N3). A significant level was considered p <0.05., Result: The mean age of patients was 48.18 ± 4.6 years, with 5.3-5.8 years duration of T2DM. After the intervention, the mean fasting blood glucose (FBG) level reached 198.53 ± 48.11 to 170.93 ± 37.41, which was significant (p <0.0001). Also, hemoglobin A1C level reached from 8.49 ± 0.9 to 7.96 ± 0.58, which was significant (p <0.0001). Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) demonstrating a significant reduction of IR levels after intervention with ferrous sulfate tablets (p <0.018)., Conclusions: IDA treatment in patients with T2DM can significantly reduce the BG and IR levels. To better control BG, checking iron status and its correction may provide better clinical outcomes in these patients., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2024
- Full Text
- View/download PDF
3. Hepatic Involvement as Hyperbilirubinemia in Patients with COVID-19: Case Series from Iran.
- Author
-
Hormati A, Ghadir MR, Saeidi M, Aminnejad R, Afifian M, and Ahmadpour S
- Subjects
- Humans, Hyperbilirubinemia epidemiology, Hyperbilirubinemia etiology, Iran epidemiology, SARS-CoV-2, Tomography, X-Ray Computed, COVID-19
- Abstract
Background: After the spread of novel coronavirus disease 2019 (COVID-19) from Wuhan to Iran, gastroenterology clinics, was faced with a large number of patients who were suspected of being infected with the SARS-CoV-2. Among refereed patient, the incidence of pure hyperbilirubinemia as rare gastrointestinal (GI) symptoms was obvious., Methods: In this case series, we have reported the clinical data in details for patients with COVID-19 who have been admitted to the Shahid Beheshti Hospital in Qom city, from 3 March to 3 August 2020. COVID infection, be confirmed by using real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) and chest computed tomography (CT) scan, as well., Results: According to the clinical findings, pure hyperbilirubinemia may consider as rare gastrointestinal (GI) symptom of COVID-19. However, it is possible that the other GI enzymes values fall in to the normal range., Conclusion: In some infected patients, GI physicians may face hepatic involvement as pure hyperbilirubinemia. At the age of COVID-19 crisis, all GI physicians should be aware of the possible occurrence of hepatic involvement as an important prognosis of COVID pneumonia and it should be exactly addressed in new referred patients to GI clinic., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2021
- Full Text
- View/download PDF
4. Clinical Manifestations of Gastrointestinal Symptoms in COVID-19 Patients: An Integrative Review.
- Author
-
Abbasinia M, Hormati A, Eshagh Hossaini SK, Foroghi Ghomi SY, Zamani F, Afifian M, and Ahmadpour S
- Subjects
- China epidemiology, Humans, Incidence, Iran epidemiology, Prevalence, COVID-19 complications, COVID-19 epidemiology, Gastrointestinal Diseases epidemiology, Gastrointestinal Diseases virology
- Abstract
After the outbreak of novel coronavirus disease 2019 (COVID-19) in Wuhan, China, its spread to other countries is rapidly increasing. In this integrative review, we report the prevalence of gastrointestinal symptoms in patients with COVID-19. For this purpose, available articles on gastrointestinal manifestations in patients with COVID-19, which were reported from China, were reviewed. All reviewed articles were searched from December 11, 2019, to June 20, 2020, based on specific key words. Related findings in these articles show that the main target of COVID-19 is lung tissue, as after the virus enters the body, it mainly causes respiratory symptoms in affected patients. But in addition to respiratory symptoms, it is possible that, over time, these patients present with other symptoms, the most obvious of which are gastrointestinal symptoms. It is well documented that diarrhea and vomiting are the most common gastrointestinal symptoms in COVID-19 patients. As part of this report, we also look at the incidence and frequency of gastrointestinal symptoms in COVID-19 patients in Iran. The results can be used by providers as a guideline for better management of gastrointestinal symptoms in these patients., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2021 Society of Gastroenterology Nurses and Associates.)
- Published
- 2021
- Full Text
- View/download PDF
5. Clinical Manifestation of Patients Who Died Due to COVID-19; A Retrospective Study from Qom-Iran.
- Author
-
Hormati A, Foroghi Ghomi SY, Sohrabi M, Jafari S, Jabbari A, Aminnejad R, Afifian M, RakhshanKhah E, and Ahmadpour S
- Subjects
- Aged, Female, Humans, Iran epidemiology, Male, Retrospective Studies, Survival Rate trends, COVID-19 epidemiology, Hospitalization statistics & numerical data, Pandemics, SARS-CoV-2
- Abstract
Background: The coronavirus disease 2019 (COVID-19) has become a pandemic health problem worldwide. In this study, we attempted to explain the clinical and laboratories characteristics of non-surviving patients, to identify the probable factors affecting disease progression., Methods: In a retrospective study, we assessed the data from dead adult patients who were hospitalized and laboratory diagnosed with COVID-19 during March 2020. The data were obtained from electronic medical records. Moreover, a checklist including demographic, clinical, laboratorial, imaging, and treatment data was completed for each one of the patients. In case of lack of information, a member of the research team contacted the first-degree relatives via phone., Results: Totally, 50 patients were enrolled in this study. The mean age was 68.0 ± 14.1 years. Of them, 29 (58%) patients were male. Notably, the median (IQR) hospitalization time was 4.0 (2.7-6.2) days and the duration between the first symptoms to death was 10.0 (5.0-14.5) days. Also, pre-existing morbidity was reported in 42 (84%) patients, and hypertension was the most common one with 28 (54%) patients. Interestingly, body temperature more than 37.5°C was reported in only 20 (40%) patients. Nevertheless, neutrophilia (≥7109/L) and lymphopenia (<1.0 109/L) were observed in 27 (54%) and 29 (58%) patients, respectively. Also, elevated levels of creatinine, lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were common, which may be indicators of aggravation of the patients' status., Conclusion: Besides age and underlying diseases, elevated creatinine level, neutrophil count, and the inflammatory indices along with the reduced lymphocyte count can be considered as indicators of disease progression. Hence, they should be considered for admission and surveillance of patients., (© 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.)
- Published
- 2020
- Full Text
- View/download PDF
6. Adding ursodeoxycholic acid to the endoscopic treatment and common bile duct stenting for large and multiple biliary stones: Will it improve the outcomes?
- Author
-
Hormati A, Ghadir MR, Sarkeshikian SS, Alemi F, Moghaddam M, Ahmadpour S, Mohammadbeigi A, and Sivandzadeh GR
- Subjects
- Aged, Common Bile Duct, Humans, Iran, Treatment Outcome, Cholangiopancreatography, Endoscopic Retrograde adverse effects, Sphincterotomy, Endoscopic adverse effects, Ursodeoxycholic Acid therapeutic use
- Abstract
Background: The role of common bile duct (CBD) stenting in the establishment of bile stream in the elderly patients and the ones who are not good candidates for surgery due to not responding to treatments was well documented in previous studies. The current study aimed at investigating the effect of adding Ursodeoxycholic acid (UDCA) to CBD stenting alone in order to reduce the size of large and multiple CBD stones., Methods: Clinical outcomes including success rates in CBD stones clearance, incidence of pancreatitis, perforation, bleeding, as well as, decrease in size of stones and liver enzymes after a two-month period were assessed in the UDCA + CBD stenting group., Results: A total of 64 patients referring to Shahid Beheshti Hospital in Qom, Iran with multiple or large CBD stones (above three or larger than 15 mm) received standard endoscopic therapies and UDCA + CBD stenting (group B) and controls only received standard endoscopic therapies with only CBD stenting (group A). The mean reduction in the size of stones in group B was significantly higher than that of group A (3.22 ± 1.31 vs 4.09 ± 1.87 mm) (p = 0.034). There was no difference in the incidence rate of complications including pancreatitis, cholangitis, bleeding, and perforation between the two groups (P > 0.05)., Conclusion: Adding UDCA to CBD stenting, due to decrease in the stone size and subsequently facilitation of the stones outlet, can be considered as the first-line treatment for patients with large and multiple CBD stones. Also, in the cases with large or multi stones may be effective in reducing size and subsequently stone retrieval. Trial registry The study protocol was approved by the Ethics Committee of Qom University of Medical Sciences (ethical code: IR.MUQ.REC.1397.075); the study was also registered in the Iranian Registry of Clinical Trials (No. IRCT20161205031252N8). This study adheres to CONSORT guidelines.
- Published
- 2020
- Full Text
- View/download PDF
7. Can COVID-19 present unusual GI symptoms?
- Author
-
Hormati A, Shahhamzeh A, Afifian M, Khodadust F, and Ahmadpour S
- Subjects
- Adult, Aged, Aged, 80 and over, Betacoronavirus isolation & purification, COVID-19, COVID-19 Testing, COVID-19 Vaccines, Clinical Laboratory Techniques, Coronavirus Infections diagnosis, Coronavirus Infections epidemiology, Gastrointestinal Diseases diagnosis, Gastrointestinal Diseases epidemiology, Gastrointestinal Diseases physiopathology, Humans, Iran epidemiology, Middle Aged, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral epidemiology, SARS-CoV-2, Young Adult, Coronavirus Infections physiopathology, Gastrointestinal Diseases virology, Pneumonia, Viral physiopathology
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.